Hepatitis E vaccine recombinant - GlaxoSmithKline/NIAID/Novavax/WRAIR

Drug Profile

Hepatitis E vaccine recombinant - GlaxoSmithKline/NIAID/Novavax/WRAIR

Alternative Names: GL 438

Latest Information Update: 20 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Novavax
  • Class Synthetic vaccines; Viral hepatitis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis E

Most Recent Events

  • 20 Oct 2010 No development reported - Phase-II for Hepatitis E in Nepal (IM)
  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
  • 30 Sep 2007 Development is still active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top